VanEck Pharmaceutical ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
VanEck Pharmaceutical ETF PPH
Morningstar’s Analysis PPH
Will PPH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the PPH management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of PPH’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 74.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 22.94 | 212M | Healthcare |
Novartis AG ADR | 10.55 | 98M | Healthcare |
Merck & Co Inc | 9.45 | 87M | Healthcare |
Novo Nordisk AS ADR | 5.59 | 52M | Healthcare |
Pfizer Inc | 4.74 | 44M | Healthcare |
GSK PLC ADR | 4.26 | 39M | Healthcare |
Bristol-Myers Squibb Co | 4.22 | 39M | Healthcare |
Sanofi SA ADR | 4.21 | 39M | Healthcare |
AbbVie Inc | 4.14 | 38M | Healthcare |
Johnson & Johnson | 4.11 | 38M | Healthcare |
United States